stella
Spinal Muscular AtrophyOctober 2021Summary reviewed June 2026

A One-Time Gene Therapy Helped 97% of Babies With Severe Muscle Disease Breathe Without Ventilators

Researchers tested a one-time gene therapy called onasemnogene abeparvovec in 33 babies with spinal muscular atrophy type 1. Nearly all babies (97%) survived without needing permanent breathing support at 14 months, and 44% could sit independently — outcomes that almost never happen without treatment.

What the trial was testing

The STR1VE-EU enrolled 33 patients with spinal muscular atrophy. The study was sponsored by Novartis Gene Therapies and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

97% of babies survived without permanent breathing support at 14 months, compared to just 26% without treatment.

The Lancet. Neurology · 2021 · NCT03461289

These findings — that nearly all treated babies lived without needing a ventilator, versus only 26% untreated — were published in the The Lancet. Neurology and represent the headline result of the study.

Researchers tracked outcomes across 33 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with spinal muscular atrophy, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This gene therapy is FDA-approved and available now under the brand name Zolgensma. It's given as a one-time IV infusion to babies under 2 years old with spinal muscular atrophy. If your child has been diagnosed with SMA type 1, ask your specialist about whether this treatment is right for them.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open spinal muscular atrophy trials

RecruitingObservational study

An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With Spinal Muscular Atrophy Compared With Healthy Controls: Active-NBS Study (UK)

Active-NBS is a study to evaluate the muscle development of patients with spinal muscular atrophy (SMA) who are diagnosed at birth. Medicines have become available in the last decade, and many patients are treated very early. Treatments are most effective if used before the patient develops symptoms. However, some patients may show symptoms by the time they receive treatment. This means that even with early diagnosis, they might still develop muscle weakness despite treatment. The investigators want to see when the movements of patients diagnosed at birth differ from normal development. This information will help identify the best time to give additional medicines currently being developed to support the muscle. The investigators will track the progress of up to 60 patients over a maximum of 30 months using wearable technologies which are worn at home. The investigators aim to validate their outcomes for use in this age group. The wearable devices are called Syde and Motor Assessment of an Infant in a Jumpsuit (MAIJU). They will be worn at regular intervals during the study and will not involve extra hospital visits for patients. The study will also recruit up to 30 healthy control participants and follow them for up to 30 months. This will help define normal development with use of the Syde device. Active-NBS will be conducted in the UK and internationally using a federated data model. Collaborative sites will collect harmonised data in accordance with the Active-NBS protocol, with data integration and oversight managed by the University of Oxford. International sites may contact the Oxford study team to establish collaboration.

Oxford, United Kingdom
RecruitingInterventional study

HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness

This single-arm pilot study will assess the preliminary effectiveness of an intensive motor skill intervention (HABIT-ILE) combined with functional strength training (FST) in children with SMA who are receiving disease-modifying therapies. Participants will attend a HABIT-ILE + FST summer camp for 6 hours per day over a 3-week period, totaling 90 hours of training.

New York, New York, United States